2m 2m 2m 2m 2m 2m 2m
KEROS THERAP (KROS)
NASDAQ
$10.50$0.00 (0.00%)
Price as of Jun 03, 2026 4:10 PM EDT- $222.7MMarket Cap
- -29.43%1-Year Change
- BiotechnologyIndustry
KEROS THERAP (KROS)
$10.50$0.00 (0.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 38.7M +990.31% | 3.5M +2,250.99% | 151,000 N/A | 0 -100.00% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 38.7M +990.31% | 3.5M +2,250.99% | 151,000 N/A | 0 -100.00% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -129.6M -25.33% | -173.6M +28.37% | -135.3M +55.00% | -87.3M +58.25% | |
Depreciation and Amortization Expense | 1.5M +22.78% | 1.2M +50.80% | 815,000 +20.92% | 674,000 +78.31% | |
Total Operating Expenses | 176.5M -17.67% | 214.4M +26.04% | 170.1M +48.18% | 114.8M +50.11% | |
Operating Profit | 67.6M +132.05% | -210.8M +24.06% | -169.9M +48.05% | -114.8M +103.63% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | 0 N/A | 0 +100.00% | -1,000 -75.00% | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 +100.00% | -1,000 -75.00% | |
Total Nonoperating Income and Expense | 24.3M +2.30% | 23.8M +40.30% | 16.9M +67.63% | 10.1M +2,908.61% | |
Income before Taxes | 91.9M +149.13% | -187.1M +22.26% | -153.0M +46.15% | -104.7M +84.51% | |
Income Taxes | 4.9M +1,527.67% | 300,000 N/A | 0 N/A | 0 -100.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 87.0M +146.44% | -187.4M +22.46% | -153.0M +46.15% | -104.7M +78.20% | |
Net Income from Continuing Operations Applicable to Common | 87.0M +146.44% | -187.4M +22.46% | -153.0M +46.15% | -104.7M +78.20% | |
Basic EPS and Net Income | 2.34 +146.80% | -5.00 -3.85% | -5.20 +25.30% | -4.15 +64.68% | |
Diluted EPS and Net Income | 2.30 +146.00% | -5.00 -3.85% | -5.20 +25.30% | -4.15 +64.68% | |
Basic Weighted Average Shares | 37.2M -0.58% | 37.4M +27.14% | 29.4M +16.66% | 25.2M +8.17% | |
Diluted Weighted Average Shares | 37.9M +1.13% | 37.4M +27.14% | 29.4M +16.66% | 25.2M +8.17% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 287.4M -48.67% | 559.9M +69.09% | 331.1M +18.67% | 279.0M +21.30% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 287.4M -48.67% | 559.9M +69.09% | 331.1M +18.67% | 279.0M +21.30% | |
Total Current Assets | 315.4M -46.44% | 588.9M +69.57% | 347.3M +21.53% | 285.8M +13.65% | |
Accumulated Depreciation | 4.4M +50.39% | 2.9M +71.45% | 1.7M +47.89% | 1.2M +37.47% | |
Property and Plant and Equipment and Net | 4.3M +1.42% | 4.2M +2.49% | 4.1M +104.55% | 2.0M +51.39% | |
Total Long-Term Assets | 0 -100.00% | 2.1M +0.19% | 2.1M -3.12% | 2.1M +2,482.93% | |
Total Assets | 338.0M -45.12% | 615.9M +66.44% | 370.0M +20.62% | 306.8M +20.19% | |
Income Taxes Payable | 3.4M N/A | N/A N/A | N/A N/A | 50,000 -54.55% | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 20.4M -25.63% | 27.4M +12.62% | 24.4M +47.30% | 16.5M +39.68% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 14.5M -14.26% | 16.9M +25.63% | 13.4M +4.90% | 12.8M N/A | |
Total Liabilities | 34.9M -21.30% | 44.3M +17.25% | 37.8M +28.80% | 29.4M +143.09% | |
Retained Earnings | -481.8M -15.30% | -568.8M +49.12% | -381.4M +66.97% | -228.4M +84.59% | |
Total Stockholders Equity | 303.1M -46.96% | 571.6M +72.04% | 332.2M +19.75% | 277.4M +14.08% | |
Total Shares Outstanding | 19.5M -51.81% | 40.6M +27.37% | 31.8M +15.60% | 27.5M +14.88% | |
Cash Flow | |||||
Cash from Operating Activities | 107.5M +166.83% | -160.9M +29.20% | -124.5M +77.71% | -70.1M +12.73% | |
Capital Expenditures | 1.6M -19.68% | 1.9M -21.63% | 2.5M +98.55% | 1.2M +21.19% | |
Cash from Investing Activities | -1.6M -19.68% | -1.9M -21.63% | -2.5M +98.55% | -1.2M +21.19% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -378.5M -196.59% | 391.8M +118.95% | 179.0M +48.75% | 120.3M +321.40% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | 174.57% +102.94% | -5,938.96% -94.72% | -112,543.71% N/A | N/A N/A | |
Return on Assets | 18.24% +148.00% | -38.01% -15.93% | -45.21% +21.37% | -37.25% +66.36% | |
Return on Equity | 19.90% +147.99% | -41.46% -17.40% | -50.19% +24.81% | -40.21% +72.82% | |
Revenue Growth | 990.31% -56.01% | 2,250.99% N/A | N/A N/A | -100.00% N/A | |
Current Ratio | 15.45 -27.97% | 21.45 +50.56% | 14.25 -17.49% | 17.27 -18.64% | |
Cash Ratio | 14.08 -30.98% | 20.40 +50.13% | 13.59 -19.43% | 16.86 -13.16% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow